scholarly journals Novel Poly(Adenosine Diphosphate-Ribose) Polymerase (PARP) Inhibitor, AZD2461, Down-Regulates VEGF and Induces Apoptosis in Prostate Cancer Cells

2019 ◽  
Vol 23 (5) ◽  
pp. 312-323 ◽  
Author(s):  
Saman Sargazi ◽  
Ramin Saravani ◽  
Javad Zavar Reza ◽  
Hossein Zarei Jaliani ◽  
Hamidreza Galavi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Parp Inhibitor ◽  
Adenosine Diphosphate ◽  
Prostate Cancer Cells

scholarly journals Efficacy and Mechanism of Action of Marine Alkaloid 3,10-Dibromofascaplysin in Drug-Resistant Prostate Cancer Cells

Marine Drugs ◽  
2020 ◽  
Vol 18 (12) ◽  
pp. 609
Author(s):  
Sergey A. Dyshlovoy ◽  
Moritz Kaune ◽  
Jessica Hauschild ◽  
Malte Kriegs ◽  
Konstantin Hoffer ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Anticancer Activity ◽  
Cancer Cells ◽  
Mechanism Of Action ◽  
Synergistic Effects ◽  
Parp Inhibitor ◽  
Cross Resistance ◽  
Drug Candidate ◽  
Prostate Cancer Cells ◽  
Marine Alkaloid

Efficacy and mechanism of action of marine alkaloid 3,10-dibromofascaplysin (DBF) were investigated in human prostate cancer (PCa) cells harboring different levels of drug resistance. Anticancer activity was observed across all cell lines examined without signs of cross-resistance to androgen receptor targeting agents (ARTA) or taxane based chemotherapy. Kinome analysis followed by functional investigation identified JNK1/2 to be one of the molecular targets of DBF in 22Rv1 cells. In contrast, no activation of p38 and ERK1/2 MAPKs was observed. Inhibition of the drug-induced JNK1/2 activation or of the basal p38 activity resulted in increased cytotoxicity of DBF, whereas an active ERK1/2 was identified to be important for anticancer activity of the alkaloid. Synergistic effects of DBF were observed in combination with PARP-inhibitor olaparib most likely due to the induction of ROS production by the marine alkaloid. In addition, DBF intensified effects of platinum-based drugs cisplatin and carboplatin, and taxane derivatives docetaxel and cabazitaxel. Finally, DBF inhibited AR-signaling and resensitized AR-V7-positive 22Rv1 prostate cancer cells to enzalutamide, presumably due to AR-V7 down-regulation. These findings propose DBF to be a promising novel drug candidate for the treatment of human PCa regardless of resistance to standard therapy.

scholarly journals MP81-05 CRISPR SCREENING REVEALS GENES DRIVING RESISTANCE AND SENSITIVITY TO PARP INHIBITOR IN PROSTATE CANCER CELLS

2019 ◽  
Vol 201 (Supplement 4) ◽  
Author(s):  
Tomoaki Takai* ◽  
Xiao Bai ◽  
Takuya Tsujino ◽  
Adam Kibel ◽  
Li Jia
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Parp Inhibitor ◽  
Prostate Cancer Cells

BCL2-overexpressing prostate cancer cells rely on PARP1-dependent end-joining and are sensitive to combined PARP inhibitor and radiation therapy

2018 ◽  
Vol 423 ◽  
pp. 60-70 ◽  
Author(s):  
Christoph Oing ◽  
Pierre Tennstedt ◽  
Ronald Simon ◽  
Jennifer Volquardsen ◽  
Kerstin Borgmann ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
Cancer Cells ◽  
Parp Inhibitor ◽  
Prostate Cancer Cells ◽  
End Joining

279: Inhibition of Cyclooxygenase-2 Pathway Overcomes the Heat-Resistance in Prostate Cancer Cells

2007 ◽  
Vol 177 (4S) ◽  
pp. 93-93
Author(s):  
Makoto Sumitomo ◽  
Kenji Kuroda ◽  
Takako Asano ◽  
Akio Horiguchi ◽  
Keiichi Ito ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Heat Resistance ◽  
Cancer Cells ◽  
Cyclooxygenase 2 ◽  
Prostate Cancer Cells
Sign in / Sign up

Export Citation Format

Share Document